I
India was not even a footnote in JPM 2026
January 2026
I was at the JPM health conference in SF last week - the most important bio/health gathering in the world. Pharma C-execs, biotech/techbio founders, and investors all congregate in SF to set the narratives for the year (and kick-start a superspreader event).
I had dozens of conversations and attended tens of satellite events - panels, talks, mixers.
India never came up. Not once. I started asking people explicitly. Only one person said they’d heard India mentioned, something related to contract manufacturing.
In the most relevant health/bio conference on the planet, India was not even a footnote.
Meanwhile, China dominated the entire conversation, along with AI.
Why does this matter? Moldova and Mali probably didn’t come up either.
Aside from India being one of the largest and fastest-growing markets in bio/health -
-
India likes to see herself as an emerging health/bio leader, a la ‘pharmacy of the world’. This rings hollow. Yes, we manufacture a ton of generics/vaccines but as some (like Soham Sankaran and others) have pointed out, we have not moved past the lowest rung of the value-chain. We do not compete on the global scale
-
Yet, China is dominating with the same advantages that India has in plenty. The Indian arbitrage in talent + data + speed is real. We know this well at Dognosis, where we ran a 3k ppt study in 1yr at <$100k total. India has (almost) all the ingredients to compete with China + leapfrog past the US
-
And, AI is commoditizing discovery. The bottleneck + value-capture is increasingly in clinical and real-world validation. This is exactly where India’s arbitrage lies
-
Finally, as bits and atoms are commoditized with AI and robotics, cells (and keeping them healthy for as long as possible) are the natural complement that will take larger chunks of GDP. Health/bio is one of India’s best shots to becoming rich in the 21st century.
Yet, as of 2026, we’re not even a footnote. What would it take for this to change in 2028?
II
“This may work in India but it will never scale in a first-world country. Never”
October 2026
A verbatim quote I had the pleasure of receiving from an extremely senior academic researcher at the Early Detection Conference (EDx) organized by Cancer Research UK, Stanford’s Canary Center, and OHSU that concluded this Thursday.
The context? A minute long conversation where I shared our latest data, with an unprecedented 87% sensitivity at Stage-1 and AUC of 0.962 for multiple cancers from our large 3000+ ppt study.
The researcher did not dispute the science or validity of our data or offer any reasoning on why our methodology wouldn’t scale. It was a fascinating window into a complete absence of first-principle thinking and open-mindedness.
It was also a good reminder that builders from “third-world countries” will not win by seeking approval and DEI scraps from the first-world-academia complex. We will only win by building technology and products that so thoroughly outclass the status-quo that there will be simply no choice but to adopt at scale.
The best part? We have an incredible arbitrage in talent and data, the most critical ingredients to building first-in-class and best-in-class healthcare products. With the right capital and culture, the third-world can bring-forth a whole-world where we can all live radically longer and healthier lives.
So are we building?
III
There can be a 10T alliance
in at least one timeline. how do we make it ours?
November 2025
As AI commoditises knowledge work, the share of GDP consumed by healthcare will naturally grow larger, from its already massive 10.3%. This will be one of the final accelerants to the natural arc that ends in the ushering of the age of longevity and a world economy that no longer assumes death as one of its fundamental axioms.
In the coming decade, I venture that multiple healthcare companies will cross 1 trillion dollars in valuation. One of these can be a $1T+ powerhouse that will be Indian born-and-brought-up, in roots, heart and soul.
Entertain me for a bit more, though, for I think that’s only the beginning. Indian capitalism, like many of her Asian counterparts, is radically more networked and interlocking than the corporations in West, witness the Japanese keiretsu or the Korean chaebols. You see this already in the intergenerational conglomerates like the Tata Group ($436B) and Reliance Group ($230B). Yet, there is something way more interesting than familial dynasties writ in the chai leaves, spelt with an acronym that suave global commentators are growing familiar with — UPI. It turns out that building interoperable and shared protocols that anyone can build and trade on allows you to catapult past the boring bank-and-cards driven gated financial systems into the far more exciting world of inclusive digital finance. Even more exciting is the meta-innovation primitive this uncovers - that you can have generative and free innovation borne from competition without the winner-take-all dynamics and inefficiencies of siloed monopolies. And while better plumbing for the movement of capital is a very good, useful, and necessary goal, nothing really compares with the finish line of eradicating sickness from the world and the bringing-forth of immutable good health.
So, allow me be way bolder than earlier, for it is not the season to be shy.
There will be an Indian “company“ that will outmuscle and outshadow many of her global AI, technological and energy siblings, and by 2047, power her way to be in the ranks of the world’s $10T “company” club. Though at that point, we may refer to it as the 1000T Rupee Club.
Given the sheer size of this behemoth, it will likely not look like the companies we take for granted as the status-quo today. In its purest form, it may look like an Alliance, a ‘mycelial’ network of interconnected companies of providers, pharma, (re)insurers, diagnostics, mobility, devices, software, data and AI players all working towards a common end-goal. In the best-aligned version of this, the Alliance’s bottom line benefits the most from the longer and healthier people live. And as AI, robotics, and manufacturing all become increasingly commoditised and edge closer to the limits of physics, chemistry and materials, extending human health and life span will be the endless frontier driving forward economic growth, with the Alliance at the cornerstone of the new global (and perhaps interplanetary) economy.
At the very least, you have to grant that this is, at least 1, of the infinite timelines that branch out from the moment you read this. So how do we make it ours?
ASK
Reading
On the clinical validation bottleneck
- Ruxandra Teslo, AI Won’t Automatically Accelerate Clinical Trials — Asimov Press, 2026. The clearest articulation of why better drug candidates alone won’t speed up clinical development. A direct response to Dario Amodei.
- Dario Amodei, Machines of Loving Grace — 2024. The optimistic case for AI compressing 100 years of biology into 10. Critically, Amodei himself identifies clinical trials as the binding constraint that even powerful AI can’t easily route around.
- Jack Scannell et al., Diagnosing the decline in pharmaceutical R&D efficiency — Nature Reviews Drug Discovery, 2012. The paper that coined Eroom’s Law: drug development costs double every nine years despite exponential improvements in underlying technology. The original diagnosis of the problem.
- Ruxandra Teslo & Jack Scannell, To Get More Effective Drugs, We Need More Human Trials — Macro Science, 2025. The case that the answer isn’t fewer trials with better drugs but more trials, faster and cheaper.
- Saloni Dattani, Ruxandra Teslo, Adam Kroetsch et al., The Clinical Trials Abundance Blog — ongoing. Ideas and commentary on making clinical trials more efficient.
On India as an R&D base
- Owl Posting, How do you make a 250x better vaccine at 1/10 the cost? Develop it in India. — 2025. Two-hour interview with Soham Sankaran of PopVax on why India has all the ingredients for original biotech research but almost none of it happens, and what it takes to change that.
- India is the pharmacy of the world. But we are losing the drug development race — Indian Express, March 2026. On the paradox of India’s dominance in generics alongside its near-absence in new drug development.
- Debarun Karmakar, with Rahul Sanghi and Aaryaman Vir, Getting Even — Tiger Feathers. Traces India’s broken hospital-insurer incentive structure back to its colonial origins, and profiles Even Healthcare’s attempt at a “Kaiser Permanente for India” by integrating payer and provider.